Lancet 2024 Apr 27
3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Related Questions
New answer by Medical Oncologist at Duke University (February 19, 2026)
There were many new findings from clinical trials and other research at the SABCS 2025. I summarize a few highlights.General Session 1, on Wednesday morning, December 10, 2025...